SCHEMBL34672

SCHEMBL34672

CN(C)S(=O)(=O)c1ccc(C(=O)O)cc1

nearest known ligand 0.66

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 4/20 0.66
KMT2A Q03164 2/20 0.66
SMN1; SMN2 Q16637 4/20 0.61
CA12 O43570 2/20 0.61
CA2 P00918 2/20 0.61
CA9 Q16790 2/20 0.61
RAB9A P51151 1/20 0.61
SLC22A6 Q4U2R8 1/20 0.61
SLC22A8 Q8TCC7 1/20 0.61
ABCC2 Q92887 1/20 0.61
SLC22A12 Q96S37 1/20 0.61
UGT1A7 Q9HAW7 1/20 0.61
SLC22A11 Q9NSA0 1/20 0.61
MAPT P10636 2/20 0.60
TAS2R14 Q9NYV8 2/20 0.59
CA1 P00915 1/20 0.55
CA3 P07451 1/20 0.55
CA6 P23280 1/20 0.55
CYP2C19 P33261 1/20 0.55
CA5A P35218 1/20 0.55

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3642059 0.94 CA12 (0.59) ALDH1A1KMT2ASMN1; SMN2CA12CA2
SCHEMBL5249012 0.85 SMN1; SMN2 (0.57) ALDH1A1SMN1; SMN2RAB9AMAPTGAA
SCHEMBL5561006 0.83 SMN1; SMN2 (0.56) ALDH1A1KMT2ASMN1; SMN2RAB9AMAPT
SCHEMBL25244774 0.83 LMNA (0.74) KMT2ASMN1; SMN2RAB9AMAPTLMNA
SCHEMBL25190857 0.83 LMNA (0.74) KMT2ASMN1; SMN2RAB9AMAPTLMNA
SCHEMBL25193155 0.83 LMNA (0.74) KMT2ASMN1; SMN2RAB9AMAPTLMNA
SCHEMBL17908029 0.82 TAS2R14 (0.63) ALDH1A1KMT2ASMN1; SMN2CA12CA2
SCHEMBL4639473 0.82 CA2 (0.59) ALDH1A1SMN1; SMN2CA12CA2CA9
Lithium Ion SCHEMBL22638688 0.82 CA1 (0.61) ALDH1A1SMN1; SMN2CA2RAB9AMAPT
SCHEMBL2517845 0.82 MAPT (0.55) ALDH1A1KMT2ASMN1; SMN2CA2RAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 116 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3551633-B1 SUBSTITUTED PYRAZOLOAZEPIN-4-ONES AND THEIR USE AS PHOSPHODIESTERASE INHIBITORS LEO PHARMA AS (DK) 2021-03-31 EP claimed
CN-110099905-A SUBSTITUTED PYRAZOLOAZEPIN-8-ONES AND THEIR USE AS PHOSPHODIESTERASE INHIBITORS 利奥制药有限公司 2019-08-06 CN claimed
CN-110088108-A SUBSTITUTED PYRAZOLOAZEPIN-4-ONES AND THEIR USE AS PHOSPHODIESTERASE INHIBITORS 利奥制药有限公司 2019-08-02 CN claimed
EP-4746882-A1 INHIBITORS OF SMNDC1 AND THEIR THERAPEUTIC USE CeMM - Forschungszentrum für Molekulare Medizin GmbH (AT) 2026-05-27 EP disclosed
WO-2025064683-A1 SMALL MOLECULE PROTEIN SYNTHESIS MODULATORS Interdict Bio, Inc. (US) 2025-03-27 WO disclosed
US-20250091989-A1 SMALL MOLECULE PROTEIN SYNTHESIS MODULATORS Interdict Bio, Inc. (US) 2025-03-20 US disclosed
WO-2025017207-A1 INHIBITORS OF SMNDC1 AND THEIR THERAPEUTIC USE CEMM - FORSCHUNGSZENTRUM FÜR MOLEKULARE MEDIZIN GMBH (AT) 2025-01-23 WO disclosed
US-20240254083-A1 HETEROCYCLIC TRPML1 AGONISTS AND USES THEREOF LIBRA THERAPEUTICS, INC. 2024-08-01 US disclosed
CN-110088108-B Substituted pyrazoloazepin-4-ones and their use as phosphodiesterase inhibitors 联合疗法公司 2024-06-14 CN disclosed
CN-110099905-B Substituted pyrazoloazepin-8-ones and their use as phosphodiesterase inhibitors 联合疗法公司 2024-06-14 CN disclosed
US-20240116872-A1 PYRIDYL INHIBITORS FOR HEDGEHOG SIGNALLING GENENTECH, INC. (US) 2024-04-11 US disclosed
EP-1748980-A1 PYRROLIDINE DERIVATIVES AS CB1-RECEPTOR ANTAGONISTS TANABE SEIYAKU CO., LTD. (JP) 2007-02-07 EP disclosed
US-20060063779-A1 Pyridyl inhibitors of hedgehog signalling CURIS ROYALTY LLC 2006-03-23 US disclosed
WO-2006028958-A2 PYRIDYL INHIBITORS OF HEDGEHOG SIGNALLING GENENTECH, INC. (US) 2006-03-16 WO disclosed
WO-2005115977-A1 PYRROLIDINE DERIVATIVES AS CB1-RECEPTOR ANTAGONISTS TANABE SEIYAKU CO., LTD. (JP) 2005-12-08 WO disclosed
US-6605626-B2 Benzamide inhibitors of factor Xa ELI LILLY AND COMPANY 2003-08-12 US disclosed
US-20020120007-A1 Benzamide inhibitors of factor Xa BEIGHT DOUGLAS WADE (US) 2002-08-29 US disclosed
US-6313122-B1 AS INHIBITORS OF FACTOR XA AND ARE USED AS ANTICOAGULANTS IN MAMMALS ELI LILLY AND COMPANY 2001-11-06 US disclosed
EP-1014962-A1 ANTITHROMBOTIC AGENTS ELI LILLY AND COMPANY (US) 2000-07-05 EP disclosed
WO-1999000121-A1 ANTITHROMBOTIC AGENTS ELI LILLY AND COMPANY (US) 1999-01-07 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250091989-A1 SMALL MOLECULE PROTEIN SYNTHESIS MODULATORS MYC, KRAS, NRAS ALDH1A1 2774/4885KMT2A 1878/4885SMN1; SMN2 1694/4885
US-20240254083-A1 HETEROCYCLIC TRPML1 AGONISTS AND USES THEREOF TRPM2, TRPM7, TRPM8 ALDH1A1 2748/4885KMT2A 3894/4885SMN1; SMN2 2052/4885
US-20240116872-A1 PYRIDYL INHIBITORS FOR HEDGEHOG SIGNALLING SHH, GLI1, SMO ALDH1A1 2371/4885KMT2A 1487/4885SMN1; SMN2 4106/4885
US-20020120007-A1 Benzamide inhibitors of factor Xa TFPI, F11, F12 ALDH1A1 835/4885KMT2A 2083/4885SMN1; SMN2 2752/4885
US-20060063779-A1 Pyridyl inhibitors of hedgehog signalling SHH, GLI1, SMO ALDH1A1 2407/4885KMT2A 1528/4885SMN1; SMN2 4094/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.